J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 9, Number 3, March 2017, pages 188-192

Primary Care-Based Investigation of the Effect of Sitagliptin on Blood Pressure in Hypertensive Patients With Type 2 Diabetes

Figure 1. Changes in office BP from baseline to 12 months. ^†P < 0.05, ^††P < 0.01. SBP: systolic blood pressure; DBP: diastolic blood pressure.

Figure 2. Changes in home BP from baseline to 12 months. ^†P < 0.05, ^††P < 0.01. SBP: systolic blood pressure; DBP: diastolic blood pressure.

**Table 1.** Clinical Profile of the Subjects
	Baseline
Age, weight, and duration of diabetes: mean ± SD; office BP and home BP: least squares mean ± SE. Office BP: office blood pressure; morning home BP: morning home blood pressure; evening home BP: evening home blood pressure.
Male/female	251:203
Age (years)	67.8 ± 11.3
Weight (kg)	64.9 ± 13.5
Office BP (mm Hg)
SBP	132.98 ± 0.74
DBP	75.38 ± 0.49
Morning home BP (mm Hg)
SBP	129.27 ± 1.12
DBP	74.49 ± 0.99
Evening home BP (mm Hg)
SBP	127.15 ± 1.39
DBP	71.88 ± 1.06
Duration of diabetes (years)	8.9 ± 7.2
Smoking history, n (%)	97 (21.4)
Drinking history, n (%)	148 (32.6)
Hypertension, n (%)	330 (72.7)
Dyslipidemia, n (%)	320 (70.5)
Cerebrovascular accident, n (%)	44 (9.7)
Myocardial infarction, n (%)	18 (4.0)
Angina, n (%)	41 (9.0)
Peripheral arterial disease, n (%)	13 (2.9)
Retinopathy, n (%)	31 (6.8)
Nephropathy, n (%)	72 (15.9)
Neuropathy, n (%)	35 (7.7)

Table 1. Clinical Profile of the Subjects

Baseline

Age, weight, and duration of diabetes: mean ± SD; office BP and home BP: least squares mean ± SE. Office BP: office blood pressure; morning home BP: morning home blood pressure; evening home BP: evening home blood pressure.

Male/female

251:203

Age (years)

67.8 ± 11.3

Weight (kg)

64.9 ± 13.5

Office BP (mm Hg)

SBP

132.98 ± 0.74

DBP

75.38 ± 0.49

Morning home BP (mm Hg)

SBP

129.27 ± 1.12

DBP

74.49 ± 0.99

Evening home BP (mm Hg)

SBP

127.15 ± 1.39

DBP

71.88 ± 1.06

Duration of diabetes (years)

8.9 ± 7.2

Smoking history, n (%)

97 (21.4)

Drinking history, n (%)

148 (32.6)

Hypertension, n (%)

330 (72.7)

Dyslipidemia, n (%)

320 (70.5)

Cerebrovascular accident, n (%)

44 (9.7)

Myocardial infarction, n (%)

18 (4.0)

Angina, n (%)

41 (9.0)

Peripheral arterial disease, n (%)

13 (2.9)

Retinopathy, n (%)

31 (6.8)

Nephropathy, n (%)

72 (15.9)

Neuropathy, n (%)

35 (7.7)

**Table 2.** Changes of Variables From Baseline 12 Months
	Baseline	3 months	6 months	9 months	12 months
ANOVA vs. baseline, *P < 0.01; P < 0.05. Least squares mean ± SE. Data on triglycerides and UACR were subjected to logarithmic transformation. HbA1c: hemoglobin A1c; FPG: fasting plasma glucose; PPG: postprandial plasma glucose; BMI: body mass index; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate; UACR: urinary albumin/creatinine ratio.
HbA1c (%)	7.31 ± 0.06	6.74 ± 0.05**	6.51 ± 0.05**	6.48 ± 0.05**	6.50 ± 0.05**
FPG (mg/dL)	150.75 ± 3.35	127.68 ± 2.73**	126.14 ± 2.35**	126.97 ± 2.70**	125.88 ± 2.31**
PPG (mg/dL)	188.98 ± 5.07	160.23 ± 4.05**	158.92 ± 4.35**	162.66 ± 4.31**	150.85 ± 3.60**
BMI (kg/m²)	25.15 ± 0.20	25.11 ± 0.20	25.08 ± 0.20	25.08 ± 0.20	25.07 ± 0.20
TC (mg/dL)	200.12 ± 2.39	192.82 ± 2.40**	191.77 ± 2.47**	191.73 ± 2.22**	191.92 ± 2.40**
LDL-C (mg/dL)	116.77 ± 1.70	112.00 ± 1.58**	110.94 ± 1.49**	111.04 ± 1.55**	110.85 ± 1.48**
HDL-C (mg/dL)	57.37 ± 0.78	56.13 ± 0.75*	56.32 ± 0.74	55.87 ± 0.72*	56.00 ± 0.74*
Triglycerides (mg/dL)	4.95 ± 0.03	4.84 ± 0.03**	4.86 ± 0.03**	4.87 ± 0.03**	4.85 ± 0.03**
Creatinine (mg/dL)	0.75 ± 0.01	0.76 ± 0.01*	0.77 ± 0.01**	0.78 ± 0.01**	0.78 ± 0.01**
eGFR (mL/min/1.73 m²)	75.45 ± 0.96	74.03 ± 1.04	73.05 ± 0.94**	72.56 ± 0.93**	71.91 ± 0.94**
UACR (mg/gCr)	3.02 ± 0.11	2.83 ± 0.12	2.80 ± 0.12	2.82 ± 0.11*	2.72 ± 0.13*

Table 2. Changes of Variables From Baseline 12 Months

Baseline

3 months

6 months

9 months

12 months

ANOVA vs. baseline, **P < 0.01; *P < 0.05. Least squares mean ± SE. Data on triglycerides and UACR were subjected to logarithmic transformation. HbA1c: hemoglobin A1c; FPG: fasting plasma glucose; PPG: postprandial plasma glucose; BMI: body mass index; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate; UACR: urinary albumin/creatinine ratio.

HbA1c (%)

7.31 ± 0.06

6.74 ± 0.05**

6.51 ± 0.05**

6.48 ± 0.05**

6.50 ± 0.05**

FPG (mg/dL)

150.75 ± 3.35

127.68 ± 2.73**

126.14 ± 2.35**

126.97 ± 2.70**

125.88 ± 2.31**

PPG (mg/dL)

188.98 ± 5.07

160.23 ± 4.05**

158.92 ± 4.35**

162.66 ± 4.31**

150.85 ± 3.60**

BMI (kg/m²)

25.15 ± 0.20

25.11 ± 0.20

25.08 ± 0.20

25.07 ± 0.20

TC (mg/dL)

200.12 ± 2.39

192.82 ± 2.40**

191.77 ± 2.47**

191.73 ± 2.22**

191.92 ± 2.40**

LDL-C (mg/dL)

116.77 ± 1.70

112.00 ± 1.58**

110.94 ± 1.49**

111.04 ± 1.55**

110.85 ± 1.48**

HDL-C (mg/dL)

57.37 ± 0.78

56.13 ± 0.75*

56.32 ± 0.74

55.87 ± 0.72*

56.00 ± 0.74*

Triglycerides (mg/dL)

4.95 ± 0.03

4.84 ± 0.03**

4.86 ± 0.03**

4.87 ± 0.03**

4.85 ± 0.03**

Creatinine (mg/dL)

0.75 ± 0.01

0.76 ± 0.01*

0.77 ± 0.01**

0.78 ± 0.01**

eGFR (mL/min/1.73 m²)

75.45 ± 0.96

74.03 ± 1.04

73.05 ± 0.94**

72.56 ± 0.93**

71.91 ± 0.94**

UACR (mg/gCr)

3.02 ± 0.11

2.83 ± 0.12

2.80 ± 0.12

2.82 ± 0.11*

2.72 ± 0.13*